- New Data on HIV Product Candidate, IR103 to be Presented -
CARLSBAD, Calif., April 21 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company developing
immune-based therapies for HIV and select other diseases, announced today that
three abstracts related to its product candidates have been accepted for
poster presentations at two prestigious scientific conferences this summer.
"We are accelerating an HIV immune-based therapy clinical program, and are
pleased that these two important scientific conferences are providing
platforms to share our preliminary data, especially with regard to our new
product candidate IR103," said John N. Bonfiglio, Ph.D., Chief Executive
Officer of The Immune Response Corporation. "We strongly believe in our
approach and the potential of both IR103 and REMUNE(R) as new treatment
options for people living with HIV. Our strategy is to use our current
clinical plan to develop a complete profile of both of these products."
IR103 is an immune-based therapy comprised of a gp120-depleted HIV-1
immunogen (REMUNE(R)) and a second-generation immunostimulatory
oligonucleotide adjuvant. IR103 is the subject of three accepted abstracts.
Two abstracts have been accepted to the XV International AIDS Conference to be
held in Bangkok, Thailand from July 11-16. Both abstracts, accepted as
posters, address new preclinical data on IR103. Additionally, preclinical
data on IR103 will be presented as a poster at the 12th International Congress
of Immunology to be held July 18-23 in Montreal, Canada.
"Our clinical program is moving forward on both product candidates. The
REMUNE(R) trials in Italy and in Spain are both fully enrolled and we expect
preliminary data from the Italian trial in the second quarter of 2004. These
trials are examining two different potential uses for REMUNE(R), one for newly
diagnosed or drug-naive patients and the other as a potential alternative for
patients that have been on antiretroviral drugs. We are also in the process
of initiating IR103 human trials this year," stated Georgia Theofan, Ph.D.,
Vice President of Clinical Development. "Our clinical development plan is on
target for obtaining as much new data as we can to move these products toward
commercialization."
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is developing immune-based
therapies (IBT) for HIV and select other diseases. The Company's HIV products
are based on its patented whole-killed virus technology, co-invented by
Company founder, Dr. Jonas Salk, to stimulate HIV immune responses.
REMUNE(R), currently in Phase II, is being developed as a treatment for people
with HIV. The Company has initiated development of a new IBT, IR103, which
incorporates a second-generation immunostimulatory oligonucleotide adjuvant.
The Immune Response Corporation is also developing an IBT for multiple
sclerosis (MS), NeuroVax(TM), which is currently in Phase II and has shown
potential therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web at
http://www.imnr.com
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern
and successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of
REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical
trials. These risks, among others, are set forth in The Immune Response
Corporation's SEC filings including, but not limited to, its Annual Report on
Form 10-K for the year ended December 31, 2003, and any subsequent Quarterly
Reports on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or circumstances
after today or to reflect the occurrence of unanticipated events. REMUNE(R)
is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is
a trademark of The Immune Response Corporation.
MEDIA CONTACT:
Laura Silver, Sam Brown Inc. Corporate Communications
310-551-9940
silver@sambrown.com
INVESTOR RELATIONS CONTACT:
Kathy Waller, Financial Relations Board
312-266-7800
kwaller@financialrelationsboard.com
AT THE COMPANY:
Michael K. Green, Chief Financial Officer
760-431-7080
info@imnr.com
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
Media, Laura Silver, Corporate Communications
of Sam Brown Inc., +1-310-551-9940, silver@sambrown.com; or
Investor Relations, Kathy Waller of Financial Relations Board,
+1-312-266-7800, kwaller@financialrelationsboard.com, both for
The Immune Response Corporation; or Michael K. Green, Chief
Financial Officer of The Immune Response Corporation,
+1-760-431-7080, info@imnr.com
|
